- Home
- MQY vs VALN Comparison
MQY vs VALN Comparison
Compare MQY & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQY
- VALN
- Stock Information
- Founded
- MQY 1994
- VALN 2012
- Country
- MQY United States
- VALN France
- Employees
- MQY N/A
- VALN N/A
- Industry
- MQY Investment Bankers/Brokers/Service
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MQY Finance
- VALN Health Care
- Exchange
- MQY Nasdaq
- VALN Nasdaq
- Market Cap
- MQY 776.5M
- VALN 777.9M
- IPO Year
- MQY N/A
- VALN 2021
- Fundamental
- Price
- MQY $11.81
- VALN $9.95
- Analyst Decision
- MQY
- VALN Strong Buy
- Analyst Count
- MQY 0
- VALN 4
- Target Price
- MQY N/A
- VALN $15.75
- AVG Volume (30 Days)
- MQY 184.8K
- VALN 122.0K
- Earning Date
- MQY 01-01-0001
- VALN 11-06-2025
- Dividend Yield
- MQY 4.73%
- VALN N/A
- EPS Growth
- MQY N/A
- VALN N/A
- EPS
- MQY N/A
- VALN N/A
- Revenue
- MQY N/A
- VALN $230,566,060.00
- Revenue This Year
- MQY N/A
- VALN $14.76
- Revenue Next Year
- MQY N/A
- VALN $24.11
- P/E Ratio
- MQY N/A
- VALN N/A
- Revenue Growth
- MQY N/A
- VALN 25.47
- 52 Week Low
- MQY $9.82
- VALN $3.62
- 52 Week High
- MQY $12.52
- VALN $12.25
- Technical
- Relative Strength Index (RSI)
- MQY 81.27
- VALN 59.71
- Support Level
- MQY $10.85
- VALN $8.72
- Resistance Level
- MQY $11.86
- VALN $9.19
- Average True Range (ATR)
- MQY 0.10
- VALN 0.35
- MACD
- MQY 0.06
- VALN 0.02
- Stochastic Oscillator
- MQY 94.51
- VALN 93.82
About MQY Blackrock MuniYield Quality Fund Inc.
Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.